MedTrace Logo

iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray

NCT03192501 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2024-06-25

No results posted yet for this study

Summary

This study prospectively evaluates whether the use of iCAGES (integrated CAncer GEnome Score) tool in guiding the treatment of advanced cancers is superior to current standard care or IHC-guided therapy in progress free survival (PFS),overall survival (OS),and improvement of life quality.

Conditions

Interventions

DRUG

inhibitors, ADC drugs such as tarceva, capmatinib, padcev et al for A/C group.

Choose appropriate targeted drugs according to NGS/IHC results.

Sponsors & Collaborators

  • The First Affiliated Hospital of Guangzhou Medical University

    collaborator OTHER

  • Sun Yat-sen University

    collaborator OTHER

  • Second Affiliated Hospital of Guangzhou Medical University

    lead OTHER

Principal Investigators

  • Zhenfeng Zhang, MD,PhD · Second Affiliated Hospital of Guangzhou Medical University

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-01
Primary Completion
2030-07-01
Completion
2039-07-01
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03192501 on ClinicalTrials.gov